SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Capone Mark Christopher

(Last) (First) (Middle)
320 WAKARA WAY

(Street)
SALT LAKE CITY UT 84108

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President & C.E.O.
3. Date of Earliest Transaction (Month/Day/Year)
08/01/2019
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/01/2019 M 70,672 A $23.11 511,505 D
Common Stock 08/01/2019 S(1) 70,672 D $44 440,833 D
Common Stock 08/01/2019 M 4,328 A $23.11 445,161 D
Common Stock 08/01/2019 S(1) 4,328 D $44 440,833 D
Common Stock 08/01/2019 M 58,138 A $30.34 498,971 D
Common Stock 08/01/2019 S(1) 58,138 D $44 440,833 D
Common Stock 08/01/2019 M 3,862 A $30.34 444,695 D
Common Stock 08/01/2019 S(1) 3,862 D $44 440,833 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Incentive Stock Option (right to buy) $23.11 08/01/2019 M 4,328 (2) 03/03/2020 Common Stock 4,328 $0.0 0 D
Incentive Stock Option (right to buy) $30.34 08/01/2019 M 3,862 (2) 09/15/2019 Common Stock 3,862 $0.0 0 D
Non-Qualified Stock Option (right to buy) $23.11 08/01/2019 M 70,672 (2) 03/03/2020 Common Stock 70,672 $0.0 0 D
Non-Qualified Stock Option (right to buy) $30.34 08/01/2019 M 58,138 (2) 09/15/2019 Common Stock 58,138 $0.0 0 D
Explanation of Responses:
1. This transaction was effected pursuant to a Rule 10b5-1 trading plan.
2. The combined Incentive Stock Option and Non-Qualified Stock Option grants vest 25% annually beginning on the first anniversary date of the option grant, subject to statutory ISO limitations.
By: Nahan A. Smith For: Mark C. Capone 08/02/2019
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
POWER OF ATTORNEY


Know all by these presents, that the undersigned 
hereby constitutes and appoints each of Benjamin Jackson, 
R. Bryan Riggsbee, Nathan A. Smith and Ben Wheeler 
of Myriad Genetics, Inc. the Company, and Jonathan 
L. Kravetz, Daniel Follansbee, 
Page Hubben and Anne Leland of 
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., 
signing singly, with full power of substitution, 
the undersigned s true 
and lawful attorney-in-fact to:

1	execute for and on behalf of the undersigned, 
in the undersigned s capacity as an officer, 
director and/or 10% shareholder of the Company, 
forms and authentication documents for EDGAR Filing Access;

2	do and perform any and all acts for and 
on behalf of the undersigned which may be necessary 
or desirable to complete and execute any such forms 
and authentication documents;

3	execute for and on behalf of the undersigned, 
in the undersigned s capacity as an officer, director 
and/or 10% shareholder of the Company, 
Forms 3, 4 and 5 in accordance with Section 
16a of the Securities Exchange Act of 1934, 
as amended, 
and the rules thereunder;


4	do and perform any and all acts for and on 
behalf of the undersigned which may be necessary 
or desirable to complete and execute any such 
Form 3, 4 or 5 and timely
 file such form with 
the United States Securities and Exchange Commission 
and any stock exchange or similar authority; and

5	take any other action of any type whatsoever 
in connection with the foregoing which, in the opinion 
of such attorney-in-fact, may be of benefit to, in the 
best interests of, or legally required by, the undersigned, 
it being understood that the documents executed by 
such attorney-in-fact, on behalf of the undersigned 
pursuant to this Power of Attorney, shall be in such 
form and shall contain such terms and conditions 
as such attorney-in-fact may approve in such 
attorney-in-fact s discretion.

The undersigned hereby grants to each such 
attorney-in-fact full power and authority 
to do and perform any and every act and 
thing whatsoever requisite, necessary, or 
proper to be done in the exercise of any 
of the rights and powers herein granted, 
as fully to all intents and purposes 
as the undersigned might or could do if personally 
present, with full power of substitution or 
revocation, hereby ratifying and confirming all 
that such attorney-in-fact, or such attorney-in-facts 
substitute or substitutes, shall lawfully do or cause 
to be done by virtue of this power 
of attorney and the rights and powers herein granted.  
The undersigned acknowledges that the foregoing 
attorneys-in-fact, in serving in such 
capacity at the request of the undersigned, 
are not assuming, nor is the Company assuming, 
any of the undersigned s responsibilities to comply 
with Section 16 of the Securities Exchange Act of 1934, 
as amended.

This Power of Attorney shall remain in full force 
and effect until the undersigned is no longer 
required to file Forms 3, 4 and 5 with respect 
to the undersigned s holdings of and transactions 
in securities issued by the Company, unless 
earlier revoked by the undersigned in a signed 
writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused 
this Power of Attorney to be executed this 
12 day of June 2019.

/s/ Mark C. Capone

Mark C. Capone